Pharma News
-
Cinacalcet: The growth rate is 143%, the patent period expires, and the domestic imitation is up again!
Cinacalcet, the first drug in a new class of calcimimetic compounds, was approved by the FDA in 2004 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) undergoing dialysis ( SHPT).
-
The world's pharmaceutical and chemical plant "fires"! Demand for domestic raw materials may surge! The price is raised by 1000%!
The world's pharmaceutical factories are "on fire"-the epidemic in India is out of control!
-
Forecast: These 10 medicines will sell best in 2021!
Recently, the comprehensive sales (absolute value), year-on-year growth rate (relative value), time to market, patent expiration time, indications
-
China State Drug Administration officially approved Semaglutide for type 2 diabetes
On April 29, Novo Nordisk announced that China State Drug Administration officially approved Semaglutide injection (0.5mg, 1mg pre-filled injection pen) for marketing to supplement diet and exercise to improve glycemic control in patients with type 2 diab
-
India's epidemic affects the global API supply pattern? Many listed companies responded
According to data from the Indian Ministry of Health, as of 8 o'clock on April 25, local time, there were 3,49,691 confirmed cases in the past 24 hours, setting a new record for the highest number of new cases in a single day since the outbreak in India
-
The epidemic in India is raging, and the global API supply pattern may be reshaped
Previously, the highest record for a single country in the world in a single day was 310,000 in the United States, but now, India is refreshing this record every day.
-
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg.
-
Will the fire in the Lifeon pharmaceutical warehouse affect the sales of related products?
Public information shows that Lifeon Pharmaceutical was listed on the SME Board of the Shenzhen Stock Exchange on December 15 last year, with the stock code 003020 and the issue price of 23.13 yuan per share.
-
15 million doses of Johnson & Johnson's COVID-19 vaccine are contaminated! FDA urgently stops
Recently, Emergent BioSolutions, the manufacturer of Johnson & Johnson's COVID-19 vaccine, has encountered raw material mixing and a large number of production safety issues.
-
After Remdesivir, where is the next hope?
At present, a number of COVID-19 vaccines have been approved for the market worldwide, and many countries are advancing their vaccination plans in an orderly manner. However, only one anti-coronavirus treatment drug is officially approved.
-
Policy escalation to impact China's antibiotics market
Recently, China's National Health Commission issued a Notice on Further Strengthening the Management of Anti-microbial Drugs to Curb Drug Resistance
Hot News
Echemi Partner
